3 Common Medications Deemed More Dangerous Than Useful by Prescrire

The medical publication Prescrire has released its annual review of medications with unfavorable risk-benefit profiles, identifying 106 drugs that are deemed more dangerous than useful. Published on December 4, 2025, the 2026 Review urges the discontinuation of these medications in favor of safer or more effective treatment options.

Of the 106 drugs identified in the latest assessment, 89 are currently marketed in France. The review is designed to assist healthcare providers and patients in choosing high-quality care while preventing patients from being exposed to disproportionate risks.

Criteria for Medication Assessment

Prescrire categorizes the flagged medications based on specific failures in their benefit-risk balance. The medications listed in the December 4, 2025, report fall into one of four primary categories:

• Drugs that have proven effectiveness but carry risks that are disproportionate to their benefits.
• Older medications that have been superseded by newer alternatives that are safer.
• Recent medications that offer a less favorable benefit-risk balance when compared to established treatments.
• Drugs that demonstrate efficacy no better than a placebo yet still pose the potential for serious adverse effects.

The publication states that this critical assessment aims to help choose quality care, not to harm patients and to avoid putting them at disproportionate risk.

Public Health Context and Surveillance

This review marks the 14th consecutive year that Prescrire has analyzed and identified drugs to avoid. The ongoing process emphasizes the necessity of post-market surveillance to identify risks that may not have been apparent during initial clinical trials. The publication cites the case of Vioxx as a real-world example of why continuous monitoring of medications after they reach the market is essential for patient safety.

The assessment focuses on the net clinical benefit of each medication, weighing the potential for therapeutic advantage against the likelihood and severity of harm. When a drug is found to be more dangerous than beneficial, Prescrire recommends that it should not be used.

By identifying these unfavorable profiles, the review provides a framework for healthcare professionals to evaluate current prescriptions and transition patients toward superior medical alternatives.